Results 81 to 90 of about 3,811,568 (245)

Localized Prostate Cancer Therapy: Tumor Microenvironment‐Activated Spermine Hydrogel With Real‐Time Autonomous Fluorescence Sensing

Chemistry – A European Journal, EarlyView.
First tumor microenvironment (TME)‐responsive spermine‐loaded hydrogel with autonomous sensing for advanced local therapy of prostate cancer (PCa) is developed. Spermine can be released from the hydrogel to kill the prostate cancer cells specifically under acidic TME.
Ho‐Fai Chau, Wing‐Sze Tam, Gengguo Deng, Yik Hoi Yeung, Christine Yim Ping Wong, Ka Lo Cheng, Zhengxiao Liu, Lijia Yao, Yi Wang, Angelo H. All, Chi‐Fai Ng, Jinming Di, Ka‐Leung Wong   +12 more
wiley   +1 more source

A Nitric Oxide–Based STING Agonist Nanoadjuvant With ICD‐Derived Membrane Antigens Unleashes Robust Antitumor Immunity

Exploration, EarlyView.
Schematic illustration of the synergistic antitumor mechanism of Im@NOnanoPL combined with αPD‐1 therapy. The Im@NOnanoPL nanovaccine targets lymph nodes via ICD‐derived tumor cell membranes, delivering personalized tumor antigens. It releases NO gas to enhance MHC‐I expression and activate the STING pathway, thereby potentiating anti‐tumor immunity in
Shuyu Xu, Yang Song, Tianjiao Zhang, Yan Wang, Mengxin Wang, Xinxin Xie, Qingfeng Chen, Xiaolong Liang   +7 more
wiley   +1 more source

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2019
Most prostate cancers are androgen-sensitive malignancies whose growths depend on the transcriptional activity of the androgen receptor (AR). In the 1940s, Charles Huggins demonstrated that the surgical removal of testes in men can result in a dramatic ...
Qin Feng, Bin He, Bin He
doaj   +1 more source

EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1)

, 2017
Recent studies have shown that docetaxel-based chemotherapy confers a survival benefit in patients with castration-resistant prostate cancer (PC). Also epidermal growth factor receptor (EGFR) was found to have multiple roles in prostatic tumorigenesis ...
Hour, Tzyh-Chyuan;Chung, Shiu-Dong;Kang, Wang-Yi;Lin, Ying-Chu;Chuang, Shu-Ju;Huang, A-Mei;Wu, Wen-Jeng;Huang, Shu-Pin;Huang, Chao-Yuan;Pu, Yeong-Shiau, 蒲永孝;黃昭淵   +1 more
core   +1 more source

Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment [PDF]

, 2004
Objective To establish which attributes of conservative treatments for prostate cancer are most important to men. Design Discrete choice experiment. Setting Two London hospitals. Participants 129 men with non-metastatic prostate cancer, mean age 70 years;
Bryan, S., De Winter, P, Payne, H, Sculpher, MJ, Fry, P., Emberton, M., Sculpher, M, Payne, H., Emberton, M, Bryan, Stirling, Sculpher, M., de Winter, P., Bryan, S, Fry, P   +13 more
core   +1 more source

Chemotherapy options in castration-resistant prostate cancer

Indian Journal of Urology, 2016
The treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) is evolving, with recent approvals of immune therapy, novel hormonal therapy, and bone-targeted therapy. Chemotherapy remains an essential component of the armamentarium.
Benjamin A Teply, Ralph J Hauke
openaire   +3 more sources

Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

International Journal of Cancer, EarlyView.
ABSTRACT Evidence to guide the treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with tumor harboring HRR alterations, progressed on a prior androgen ...
Lorena Incorvaia, Daniele Santini, Marc R. Matrana, Marco Maruzzo, Ray Manneh Kopp, Lorenzo Antonuzzo, Sergio Bracarda, Deniz Tural, Giuseppe Procopio, Maria T. Bourlon, Orazio Caffo, Martin Ignacio Zapata Laguado, Massimo Di Maio, Brigida Anna Maiorano, Vincenza Conteduca, Sabrina Rossetti, Helga Lipari, Thomas Büttner, Mimma Rizzo, Yüksel Ürün, Carlo Messina, Fernando Sabino Marques Monteiro, Andrey Soares, Mattia Puglisi, Alice Principi, Eleonora Lai, Giulia Mammone, Marco Stellato, Ilaria Depetris, Tancredi Didier Bazan Russo, Isadora Yasbick Spricido, Camila Bobato Lara Gismondi, Francesco Massari, Nicola Pavan, Matteo Santoni, Tarek Taha   +35 more
wiley   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

Reappraisal of glucocorticoids in castrate-resistant prostate cancer

Asian Journal of Andrology, 2014
Recent reports and discussions of preclinical prostate cancer models have emphasized the possibility that enzalutamide resistance may be mediated by glucocorticoid receptors (GR). In both in vitroand xenograft animal studies, it is possible to show that the GR is up-regulated in prostate cancer cell lines and that dexamethasone reverses enzalutamide ...
Oliver Sartor, Christopher C Parker, Johann De Bono   +2 more
openaire   +3 more sources